Distinguished in Angiosarcoma

Dr. Diana C. Medgyesy

Oncology | Hematology
Poudre Valley Medical Group LLC
255 N 30th St, 
Laramie, WY 
Accepting New Patients
Distinguished in Angiosarcoma
Poudre Valley Medical Group LLC
255 N 30th St, 
Laramie, WY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Diana Medgyesy is an Oncologist and a Hematologist in Laramie, Wyoming. Dr. Medgyesy is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Endometrial Cancer. Dr. Medgyesy is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Specialist in CO
Hospital Affiliations
Poudre Valley Hospital
Uchealth Greeley Hospital
Medical Center Of The Rockies
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

POUDRE VALLEY MEDICAL GROUP LLC
255 N 30th St, Laramie, WY 82072
Other Locations
POUDRE VALLEY MEDICAL GROUP LLC
2121 E Harmony Rd, Unit 170 Uchmg Cancer Car, Fort Collins, CO 80528

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
Enrollment Status: Approved_for_marketing
Publish Date: December 16, 2024
Intervention Type: Drug
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2023
Intervention Type: Drug
Study Drugs: Ladiratuzumab vedotin, Trastuzumab
Study Phase: Phase 1
View 6 Less Clinical Trials

1 Total Publications

Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 28, 2013
Similar Doctors
Advanced in Angiosarcoma
Dr. James C. Moore
Oncology | Hematology | Hematology Oncology
Advanced in Angiosarcoma
Dr. James C. Moore
Oncology | Hematology | Hematology Oncology

Poudre Valley Medical Group LLC

2121 E Harmony Rd, Unit 170 Uchmg Cancer Car, 
Fort Collins, CO 
 (60.9 miles away)
970-493-6337
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Moore is an Oncologist and a Hematologist in Fort Collins, Colorado. Dr. Moore is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Mantle Cell Lymphoma (MCL), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Familial Wilms Tumor 2. Dr. Moore is currently accepting new patients.

Advanced in Angiosarcoma
Dr. Regina J. Brown
Oncology | Hematology Oncology
Advanced in Angiosarcoma
Dr. Regina J. Brown
Oncology | Hematology Oncology
2121 East Harmony Road, 150, 
Fort Collins, CO 
 (60.9 miles away)
970-493-6337
Languages Spoken:
English

Regina Brown is an Oncologist and a Hematologist Oncology provider in Fort Collins, Colorado. Dr. Brown is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Paget Disease of the Breast, Intraductal Papilloma, Inflammatory Breast Cancer, and Angiosarcoma.

Advanced in Angiosarcoma
Dr. Matthew D. Sorensen
Oncology
Advanced in Angiosarcoma
Dr. Matthew D. Sorensen
Oncology

Poudre Valley Medical Group LLC

2121 E Harmony Rd, Unit 170 Uchmg Cancer Car, 
Fort Collins, CO 
 (60.9 miles away)
970-493-6337
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Sorensen is an Oncologist in Fort Collins, Colorado. Dr. Sorensen is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), Pleuropulmonary Blastoma, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Sorensen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Medgyesy's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile